Skynor Medical Secures ￥100 Million in Series B Funding

(VCBeat) Jan. 20, 2021 – Recently, Skynor Medical announced the completion of a Series B funding worth nearly 100 million yuan, this round of financing led by Zeyue Capital, with participation from Chuangban Investment and the existing investor shareholder Anlong Fund with investment. Das Capital acted as the exclusive financial adviser in the latest round.

Proceeds from the transaction will be used for the development and clinical trials of new products, market promotion and company operation, etc., therefore to accelerate the certification and localization of more than 15 products of Skynor Medical, and help the company develop business in the fields of nerve intervention and peripheral intervention, and become a platform company with a complete product line.

Founded in 2014 and located in the Shanghai International Medical Park, Skynor Medical focuses on the R&D of high-end interventional vascular products for minimally invasive therapies, with two major product lines covering neuro intervention and peripheral vascular intervention. The company is committed to providing perfect treatments for patients with stroke and peripheral artery/vein diseases.

Skynor Medical has preliminarily formed a relatively complete solution of neurointerventional devices. For ischemic stroke, the company has developed thrombectomy devices and balloon catheters for balloon dilation of intracranial arteries The access products include distal access catheters, microcatheters, balloon guide catheters, etc. Products for hemorrhagic stroke such as densely braided stent-mesh devices and stents for intracranial aneurysms are also under development. The above products are expected to be certificated in the first half of 2021.

Among the peripheral intervention products of Skynor Medical, a new generation of the self-developed peripheral stent is undergoing multi-center controlled clinical trials, with excellent preliminary clinical results. In addition, several interventional products including the balloon dilation catheter for peripheral indications have been certificated by NMPA and the PTA balloon dilation catheter is expected to be approved in February 2021.

Zeyue Capital was founded by many experts in the field of medicine and healthcare and has great experience and resources in the pharmaceutical industry. Zeyue Capital focuses on high-growth segments such as trauma repair, vascular surgeries, regenerative medicine, etc., and segments that benefit from the medical reform of China, including cellular immunotherapies for cancers, stem cell therapies, pediatrics, innovative cancer drugs, and oncology devices, elderly care, etc.

Anlong Fund invests in the life sciences and healthcare-related fields. The company keeps targeting the trillion-scale Chinese market in the life sciences and healthcare industry, focusing on China's population aging, medical reform, and high-speed development of life sciences and medical technology.